- Money Worries Top Seniors’ List of Health-Related Concerns: Poll
- Scientists Developing Vaccine Against Present and Future COVID Viruses
- ERs Often Missing Epilepsy in Kids With ‘Non-Motor’ Seizures
- Parents of Infants With Cystic Fibrosis Often Feel Confused, Unsupported: Survey
- Avoid Some ‘Project Watson’ Dog Eye Wipes Due to Infection Danger
- New Test Might Alert Pregnant Women to Preeclampsia Danger
- Combo Therapy May Be Advance Against Liver Cancer
- How ‘Unruly’ Sports Parents Harm Their Kids’ Mental Health
- Could You Spot the Silent Symptoms of Stress?
- Gas Stoves Could Leave Your Lungs Vulnerable to Nitrogen Dioxide
Combination Antibiotic Zerbaxa Approved
The combination antibiotic Zerbaxa (ceftolozane/tazobactam) has been approved by the U.S. Food and Drug Administration to treat adults with complicated abdominal infections and complicated urinary tract infections.
The approval for abdominal infections was approved in combination with another drug, metronidazole, the agency said in news release. The approval for urinary tract infection includes infection of the kidney.
Zerbaxa is the fourth antibiotic to be FDA-approved in 2014, following approval of Dalvance (dalbavancin), Sivextro (tedizolid) and Orbactiv (oritavancin).
The drug’s label includes a warning about decreased effectiveness among people with kidney impairment, the FDA said. The most common side effects reported during clinical testing included nausea, diarrhea, headache and fever.
Zerbaxa is marketed by Cubist Pharmaceuticals, based in Lexington, Mass.
More information
To learn more, visit the FDA.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.